Effect of magnetic therapy in prevention of spasticity after stroke.

To evaluate the effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) in prevention of post-stroke spasticity in Acute Middle Cerebral Artery territory infarct: An open label randomized sham control trail - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110271

Enrollment

Registered

2026-05-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G460- Middle cerebral artery syndrome

Interventions

Intervention1: Repetitive Transcranial Magnetic Stimulation (rTMS): Patient will be given 3 daily sessions of rTMS. One treatment session in this study with real rTMS will consist of 1000 pulses of 1

Eligibility

Inclusion criteria

Inclusion criteria: 1. First-time stroke. 2. Stroke in Middle Cerebral Artery territory. 3. Stroke within 7 to 30 days. 4. 18 years of age or older. 5. Ability to follow three-step directions. 6. Patients with no spasticity or minimal spasticity. 7. Sufficient ambulation or wheelchair mobility to allow subject to present to treatment and testing areas with minimum assist.

Exclusion criteria

Exclusion criteria: 1. History of seizure within the past two years. 2. Inability to follow three-step directions. 3. Anosognosia 4. Moderate to severe receptive aphasia. 5. Premorbid spasticity or neurologic impairment prior to stroke. 6. Co-morbidities impairing upper extremity function such as fracture or deformity. 7. Indwelling metal or medical devices incompatible with TMS. 8. Pregnancy. 9. Bi-hemispheric or multifocal stroke. 10. Severe dementia. 11. Neurolytic injection within the 3 months prior to onset of study or planned neurolytic injection during study period.

Design outcomes

Primary

Measure	Time frame
Change in Baseline modified Modified Ashworth Scale score from baseline (pre-treatment) to 1 month (post-treatment) and follow up at 3 months.Timepoint: Baseline (pre-treatment) to 1 month (post-treatment) and follow up at 3 months.	—

Secondary

Measure	Time frame
1. Motor function improvement will be assessed through a digital hand dynamometer at the end of 1 month & 3-month follow-up. Strength of the hand grip will be measured in kilograms (kg). 2. Change in Baseline performance on the Barthel Index (BI) Scale from baseline to the end of one month & 3-month follow-up. 3.Post stroke pain, if present will be assessed using Numerical Rating Scale (NRS) (Score: 0 to 10). This will be assessed across all joints. Comparison will be done at 1 month & 3-month follow-up. 4. Aphasia, if present will be compared using Aphasia Severity Rating (ASR) (Score: 0 to 4). Comparison will be done at 1 month & 3-month follow-up. Timepoint: Baseline, 1 months, 3 months	—

Measure

Time frame

1. Motor function improvement will be assessed through a digital hand dynamometer at the end of 1 month & 3-month follow-up. Strength of the hand grip will be measured in kilograms (kg). 2. Change in Baseline performance on the Barthel Index (BI) Scale from baseline to the end of one month & 3-month follow-up. 3.Post stroke pain, if present will be assessed using Numerical Rating Scale (NRS) (Score: 0 to 10). This will be assessed across all joints. Comparison will be done at 1 month & 3-month follow-up. 4. Aphasia, if present will be compared using Aphasia Severity Rating (ASR) (Score: 0 to 4). Comparison will be done at 1 month & 3-month follow-up. Timepoint: Baseline, 1 months, 3 months

—

Countries

India

Contacts

Public ContactDr Rahul P Kulkarni

AIIMS Bhubaneswar

sanjeev_bhoi@rediffmail.com8861401762

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026